CBIO CBIO
Company Profile ↓Company Overview
CBIO (CBIO) is a publicly traded company listed on . The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Recent Developments
- 5-Year Trend Long-term compounding — revenue CAGR -3.7%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | -3.72% |
| 1 Year: | - |
Stock Price Performance
| 1 Year: | +33.19% |
| 6 Months: | +65.30% |
| 3 Months: | -12.78% |
| 1 Month: | -7.40% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMAAbove
- RSI (14)47.55 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
- Revenue declined at -3.7% CAGR over 5 years.
- Trading 41.5% below its 52-week high.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Sep 2015 | Dec 2015 | Mar 2016 | Jun 2016 | Sep 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 | 0 | 0 | 10.84M | 1.04M | 0 |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 21.03M | 25.89M | 102.34M | 25.77M | 26.36M |
| Operating Income | -7.17M | - | -7.58M | -8.09M | -7.89M | - | -7.97M | -8.24M | -8.18M | - | -12.15M | -12.15M | -12.52M | - | -15.13M | -16.82M | -14.11M | - | -8.11M | -14.11M | -13.73M | -14.28M | -14.40M | -17.34M | -14.66M | -13.35M | -8.77M | -10.94M | -8.93M | -9.81M | -11.12M | -10.36M | -11.23M | - | -14.22M | -21.03M | -25.89M | -91.49M | -24.73M | -26.36M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -20.71M | -24.58M | -90.34M | -23.22M | -24.77M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.07M | 0 | 0 | 0 | 0 |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -21.79M | -24.61M | -90.40M | -23.28M | -24.84M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 | - | - | - | - | - | - |
| Net Income | -7.17M | -8.88M | -7.55M | -8.07M | -7.85M | -8.33M | -7.93M | -8.14M | -7.95M | -9.26M | -11.51M | -11.28M | -11.58M | -13.91M | -14.08M | -15.83M | -13.25M | -14.73M | -7.66M | -14.08M | -13.72M | -14.27M | -14.40M | -17.33M | -14.65M | -13.27M | -8.52M | -10.36M | -8.26M | -9.20M | -10.74M | -10.10M | -9.82M | - | -15.15M | -21.79M | -24.61M | -92.40M | -23.28M | -24.84M |
| Diluted EPS | -0.38 | -0.47 | - | -0.41 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -0.28 | -0.28 | -0.34 | -0.28 | -0.25 | -0.16 | -0.17 | -0.13 | -0.14 | -0.04 | -0.16 | -0.15 | - | - | -4.93 | -1.27 | -4.01 | -0.70 | -0.74 |
| R&D Expense | 5.04M | - | 5.52M | 5.78M | 5.92M | - | 5.88M | 5.72M | 5.78M | - | 9.30M | 9.30M | 9.73M | - | 11.77M | 13.07M | 10.72M | - | 12.67M | 9.87M | 10.67M | 11.15M | 10.17M | 13.28M | 9.60M | 7.97M | 4.92M | 5.42M | 4.07M | 5.29M | 6.03M | 6.29M | 1.72M | 14.03M | 10.63M | 12.08M | 20.35M | - | 17.90M | 19.39M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 15.26M | 3.99M | 15.03M | 20.07M | 18.50K | - | - | - | 10.16M | 1.16M | 75.00K | 10.00K | - | 10.84M |
| Operating Income | 3.64M | -10.61M | -11.14M | -12.78M | -31.91M | -33.93M | -51.50M | -61.39M | -51.51M | -63.45M | -47.40M | -39.28M | -40.04M | -152.63M |
| Net Income | 3.66M | -10.61M | -11.12M | -12.77M | -31.81M | -33.28M | -48.27M | -57.89M | -51.03M | -63.43M | -46.69M | -36.90M | -37.88M | -153.94M |
| Diluted EPS | 0.33 | -8.87 | -0.60 | - | - | - | - | -1.34 | -1.12 | -1.23 | -0.89 | -0.58 | -0.59 | - |
| R&D Expense | 9.44M | 11.70M | 19.57M | 25.05M | 23.28M | 24.10M | 40.09M | 47.03M | 44.93M | 47.49M | 28.39M | 20.07M | 14.26M | 138.09M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Sep 2024 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 5.28M | 57.26M | 48.46M | 42.39M | 128.58M | 214.84M | 167.97M | 142.83M | 94.35M | 51.81M | 45.32M | - | 35.62M | 240.29M |
| Total Equity | 8.46M | 12.53M | 2.91M | 50.80M | 40.47M | 35.30M | 119.70M | 205.46M | 154.20M | 128.22M | 81.60M | 42.93M | 38.41M | 0 | -15.48M | 203.01M |
| Cash & Equivalents | 28.17M | 17.37M | 2.31M | 55.20M | 46.80M | 40.04M | 123.92M | 209.92M | 158.20M | 137.04M | 90.25M | 47.87M | 41.79M | - | 34.77M | 213.19M |
| Total Liabilities | - | - | 2.38M | 6.46M | 7.99M | 7.09M | 8.88M | 9.37M | 13.77M | 14.61M | 12.74M | 8.88M | 6.90M | - | 47.10M | 37.28M |
| Current Liabilities | - | - | 2.28M | 6.46M | 7.75M | 6.33M | 8.17M | 8.76M | 10.95M | 12.43M | 11.82M | 8.88M | 6.84M | - | 9.61M | 36.07M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | -8.24M | -29.73M | -29.77M | -43.33M | -51.98M | -39.24M | -57.49M | -46.46M | -34.88M | -31.10M | -71.53M |
| Investing Cash Flow | - | - | - | -268.59K | -704.20K | -294.11K | -125.62K | -144.93K | -68.51K | -14.94K | -84.19K | -21.39K | 20.03K | -72.92M |
| Financing Cash Flow | - | - | - | 114.12K | 23.67M | 113.95M | 129.45M | 412.91K | 18.14M | 10.72M | 4.16M | 28.82M | 5.40K | 322.98M |
| Capital Expenditure | -316.18K | -82.09K | -212.60K | -268.59K | -704.20K | -294.11K | -125.62K | -144.93K | -68.51K | -14.94K | -84.19K | -21.39K | -9.97K | -919.00K |
| Free Cash Flow | - | - | - | -8.51M | -30.44M | -30.06M | -43.46M | -52.13M | -39.31M | -57.50M | -46.54M | -34.90M | -31.11M | -72.45M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Margin % | 23.8% | -265.7% | -74.1% | -63.7% | -172,505.3% | - | - | - | -506.8% | -5,470.7% | -63,204.4% | -392,752.9% | - | -1,407.5% |
| Net Margin % | 24.0% | -265.6% | -74.0% | -63.6% | -171,945.1% | - | - | - | -502.1% | -5,469.0% | -62,251.7% | -368,994.2% | - | -1,419.6% |
| ROE % | 29.2% | -364.8% | -21.9% | -31.6% | -90.1% | -27.8% | -23.5% | -37.5% | -39.8% | -77.7% | -108.8% | -96.1% | 244.7% | -75.8% |
| ROCE % | - | -353.1% | -21.9% | -31.4% | -88.5% | -28.2% | -25.0% | -39.1% | -39.5% | -76.9% | -110.4% | -102.1% | -154.0% | -74.7% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for CBIO
CRESCENT BIOPHARMA, INC. SEC Filing (Aug 3, 2026) - Stock Titan
<a href="https://news.google.com/rss/articles/CBMipAFBVV95cUxOREhKVDRBNE9rMWZ4RWxIVFhLTFlLOVJOaDM3bzdXNXZrTkUzT2k4TlQwTXV6UDZhSGNfbkZPX3hSMlVjU2hoSW9nOUV3RFlxd0xaQlY3clpIeGVjRUw5RENqN3M5VDlGV2VqaUFxdmJyOUJaVUl6NnhZUWdCSEVFd2F2QldBeDZrbzZ5cG…
Crescent Biopharma: Q2 Earnings Snapshot - kens5.com
<a href="https://news.google.com/rss/articles/CBMi1AFBVV95cUxPQlpZZ1V3MzNpTy1WSVBaelhXQWNuS2s4U2V0SUpyMmZLMnAzOTJVWWNyNmZZOU5SVGQxaXN2ZXBtZlJXUS0wTVZ1NnFBbDM3emloVmhERl9BU1dOWkM5OG9qcXFkbWt3MEpOQlFiOXo4VWY5WkpuQkIybUdPWW9hY2s0TzJMSnlVYnFlbD…
Crescent Biopharma Stock Surges 86%, With A 7-Day Winning Spree - Trefis
<a href="https://news.google.com/rss/articles/CBMivwFBVV95cUxQV09BbGpZclhid29hckFEMVBpZ1pOQUVENjhOelZIci0wa05WQ0xDdTJDeTE1cTc4bmtCc2ROazNHajUySzhFZkNJX1N1U2VJcHBtSUtFYlJuMl9zbmhOM0hDbmlYMDZRQ0stdjRRMEg2dTJicVBXcXdwcVZENzZJSkVZbnEyam5fR3RCaE…
Crescent Biopharma Prices $125 Million Public Offering of Ordinary Shares and Pre-Funded Warrants - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMizAFBVV95cUxQdFUtSDRSVzBETkctZ05oOXZZOFhwbmFONFRNbW94bF9scHNmbDc3NWh2Si00bXpwRF9FdGNHVHRrQnRrMU9XdmMxdG96WUotdjYxZ2IzbGlHV3lkQ2MwU3lnNjZ0WERoWTdoUnNnVnh1ckZVV0xpWEx1U3hfMlhCejdnRUVvdS1MdzhZM3…
Crescent Biopharma (CBIO) Stock Analysis Report | Ratings, Financials & Performance - Benzinga España
<a href="https://news.google.com/rss/articles/CBMiU0FVX3lxTFBQU203ZjFidjc4Rng1dVhfbTdVRWx2eFJRZHU5ay1BM3lLYkhuRlNDQjF2dVdrYlpYUWwwbFJka2g3U2w0TVl3SGNueVU5RDR0dGcw?oc=5" target="_blank">Crescent Biopharma (CBIO) Stock Analysis Report | Ratin…
Crescent Biopharma Rings the Nasdaq Stock Market Closing Bell - Nasdaq
<a href="https://news.google.com/rss/articles/CBMikAFBVV95cUxOQlNWRlpoUG93SDV1a2dzWkJwQjE4TExNUVU4Tk13aUxKQmZ5RVhET3dzYVpsNmpMZVpqQ2U1eUVTeFNmSGJBLUFCU2d5SmZ1QTZxWDVOWnViMS1yd3hkelo3ekEyeEJmb3hnVmNrWFQzYTZWNXVXclFZTWRHamtZcXBNQ1lfcTlCbHA0bV…
CBIO — Frequently Asked Questions
What is the current share price of CBIO?
As of 2026-08-05 17:25 PDT, CBIO trades at $15.77 on NASDAQ/NYSE. Its 52-week range is $8.94 to $26.98.
What is the P/E ratio of CBIO?
CBIO trades at a trailing price-to-earnings (P/E) ratio of -26.73.
What is the return on equity (ROE) of CBIO?
CBIO has a return on equity (ROE) of -75.83%. Its return on capital employed (ROCE) is -74.74%.
Is CBIO a good stock to buy?
This page provides a data-driven analysis of CBIO, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.